With over 20 research initiatives underway, we are hoping to validate new alternative patient therapies and to advance the science of cannabis.
Summary of Experience of Medical Marijuana Use in Canadian Military Veterans Diagnosed with Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder (PTSD) is a mental illness related to a traumatic event. It is a severe disorder which can be chronic and can result in disabilities at the social, occupational and interpersonal level. PTSD symptoms are intrusive symptoms such as flashbacks, avoidance symptoms, and arousal symptoms (anger). PTSD is treated with pharmacotherapy and psychotherapy. However, many do not respond to these treatments. The objective of this study is to describe changes in patient-reported outcomes (PRO) and PTSD related medication consumption of military veterans with PTSD undergoing treatment with medical marijuana.
Head Researcher: Dr. Paul Smith, MD
Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol
Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-inflammatory and anti-anxiety drug. However, a bell-shaped dose-response was observed, which limits its clinical use. In the present study, In stark contrast to purified CBD, the clone 202 (Avidekel) extract, provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, making this plant medicine ideal for clinical uses.
Head Researcher: Dr R. Gallily. Zhannah Yekhtin, Lumír Ondřej Hanuš
Location: The Lautenberg Center for General and Tumor Immunology, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.
Published in: Scientific Research Vol. 6 No.2, February 2015
Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Prospective Placebo-Controlled Study.
Clinical research study that was conducted to examine whether or not cannabis brings about clinical and bio-chemical improvement in cases of active Crohn’s disease, without the use of steroids.
Head Researcher: Dr. Timna Naftali
Location: Gastroenterology Hospital: Meir Medical Center, Kfar Saba, Israel.
Published in: Clinical Gastroenterology and Hepatology, Volume 11, Issue 10, Pages 1276-1280.e1, October 2013.
The Effects of Cannabis on Appetite and Blood Indices of Geriatric Patients
A long-term observational follow-up conducted to collect data from elderly nursing home patients that regularly use medical cannabis. The study measures parameters such as: nutritional blood work, caloric intake, weight, prescription drug usage, sepsis, trembling, spasticity, and quality of life measurements (mood, sleeping habits, etc.)
Head Researcher: Dr. Moshe Geitzen, Geriatrics
Location: Hadarim Nursing Home, Kibbutz Naan
Status: The results of the first two years of the follow-up were presented at two geriatrics conferences and very well received. The follow-up has been extended for a third year based on the positive feedback from the geriatrics research community.
Treatment of Crohn’s Disease with Cannabis: An Observational Study
The retrospective research study was conducted by interviewing 20 patients suffering from Crohn’s disease that were granted a license for medical cannabis treatment to measure the effectiveness of the treatment. The study has found very positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, blood in stool samples, pain, etc.)
Head Researcher: Dr. Timna Naftali, Gastroenterology
Location: Meir Medical Center, Kfar Saba, Israel.
Published in: IMAJ – The Israel Medical Association Journal, Volume 13, Pages 455-458, August 2011.
The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report.
The purpose of this case report is to describe a patient with a preoperative complex pain syndrome who underwent liver transplantation and was able to reduce his opioid consumption significantly following the initiation of treatment with medical cannabis.